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Abstract
Nicotinic acetylcholine receptors (nAChRs) containing the α5 subunit are of interest because
genome-wide association studies and candidate gene studies have identified polymorphisms in the
α5 gene that are linked to an increased risk for nicotine dependence, lung cancer, and/or alcohol
addiction. To probe the functional impact of an α5 subunit on nAChRs, a method to prepare a
homogeneous population of α5-containing receptors must be developed. Here we use a gain of
function (9') mutation to isolate populations of α5-containing nAChRs for characterization by
electrophysiology. We find that the α5 subunit modulates nAChR rectification when co-assembled
with α4 and β2 subunits. We also probe the α5–α4 interface for possible ligand binding
interactions. We find that mutations expected to ablate an agonist binding site involving the α5
subunit have no impact on receptor function. The most straightforward interpretation of this
observation is that agonists do not bind at the α5–α4 interface, in contrast to what has recently
been demonstrated for the α4–α4 interface in related receptors. In addition, our mutational results
suggest that the α5 subunit does not replace the α4 or β2 subunits and is relegated to occupying
only the auxiliary position of the pentameric receptor.
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1. Introduction
Nicotinic acetylcholine receptors (nAChRs) are widespread in the peripheral and central
nervous systems. Because these receptors can be activated by nicotine as well as their native
ligand acetylcholine, they have been associated with several health-related phenomena.
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Nicotine is the major addictive component of tobacco, and chronic tobacco use (smoking)
has been implicated in many types of cancer as well as heart disease. Other related
phenomena include an inverse correlation between smoking and Parkinson's disease and the
observation that patients with autosomal dominant nocturnal frontal lobe epilepsy who
smoke have fewer seizures (Brodtkorb and Picard, 2006).
nAChRs belong to the Cys-loop family of ionotropic receptors, which share a pentameric
architecture arranged around a central ion-permeable pore. Many diverse subunit
combinations can form functional receptors, and these combinations have distinct
pharmacologies concerning responses to acute applications and chronic or repeated
applications of nicotinic drugs. Neuronal nAChRs are composed of α2–α11 and β2–β4
subunits and assemble as α plus β or α only pentamers. The neuronal α4β2 receptor subtype
is one of the two most abundant nAChRs in the central nervous system (CNS). Two α4β2
pentameric stoichiometries are known: (α4β2)2(β2) and (α4β2)2(α4), which shall be referred
to as A2B3 and A3B2, respectively (Nelson et al., 2003). Subunit stoichiometry of nAChRs
is important in determining pharmacology, stability, and subcellular location. The A2B3
stoichiometry displays higher sensitivity to nicotine and has been proposed to play an
especially prominent role in nicotine addiction.
Several brain regions express receptors that contain an α5 subunit (α5* receptors), including
the substantia nigra pars compacta, subthalamic nucleus, medial habenula, prefrontal cortex,
and hippocampus. Receptors containing α5 play a part in nicotine self-administration and
nicotine withdrawal (Fowler et al., 2011). These receptors are also important for dopamine
release and attention tasks (Bailey et al., 2010; Gotti et al., 2006; Salminen et al., 2004). The
α4β2α5 receptors are more permeable to Ca2+ than α4β2 receptors and have a higher
sensitivity to nicotine (Kuryatov et al., 2008). The α5 subunit has been assumed to occupy
the fifth “auxiliary” position in pentameric receptors, and it has not previously been thought
to participate in forming a functional agonist binding site. However, recent studies have
proposed that a low affinity binding site exists in the A3B2 α4β2 receptor at the α4–α4
interface (Fig. 1) (Harpsoe et al., 2011; Mazzaferro et al., 2011; Rohde et al., 2012), in
addition to the higher affinity binding sites at the α4–β2 interface. This new binding location
utilizes an auxiliary subunit interface, leading to questions as to whether α5 can participate
in a similar motif.
Given the precise localization and unique functional properties of α5* receptors, α5 presents
itself as a valuable therapeutic target. However, currently there are no pharmacological
ligands that can functionally isolate α5* receptors. If α5 does participate in a ligand-binding
site at the α5–α4 interface, this interaction would be a vital target for selective ligand
development.
2. Materials and methods
2.1. Molecular Biology
Mouse nAChR α5 wt, α5-GFP, α4 and β2 subunits were in pGEMhe. The QuikChange
protocol (Stratagene) was used for site-directed mutagenesis. Circular DNA for α5, α4 and
β2 was linearized as follows: SphI restriction enzyme for α5 plasmids and SbfI restriction
enzyme for the α4 and β2 plasmids. After purification (Qiagen), mRNA was synthesized
from linearized DNA template through run-off transcription by using the T7 mMessage
Machine kit (Ambion). Purification of mRNA was performed using QIAGEN's RNeasy
RNA purification kit.
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2.2. Electrophysiology Studies
2.2.1. Xenopus Oocyte Preparation and Injection—Xenopus laevis stage V and VI
oocytes were harvested via standard protocols (Nowak et al., 1998). The α5 mRNA was
mixed with α4 and β2 mRNA in a 10:1:1 ratio by mass and 50 nl were injected into the
oocytes delivering 40 ng of total mRNA. After injection, oocytes were incubated at 18° C in
ND96+ medium for 24–96 h. The control experiments of only α4 and β2 mRNA with a ratio
of 1:1, 1:2 and 10:1 had total mRNA amounts of 6.67 ng, 20 ng and 21 ng, respectively.
2.2.2. Chemical Preparation—Acetylcholine chloride, (−)-nicotine tartrate and
mecamylamine hydrochloride were purchased from Sigma-Aldrich and dissolved to 1 M and
0.25 M stock solutions in ND96 Ca2+ free buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5
mM HEPES at pH 7.5), respectively.
2.2.3. Electrophysiological Experimental Protocols and Recordings—
Electrophysiological recordings were performed using two electrode voltage clamp mode
with the OpusXpress 6000A (Axon Instruments). The holding potential was −60 mV. All
recordings involving α5* receptors and α4β2 receptors used the ND96 Ca2+ free solution as
the running buffer. All measurements used 1 mL of drug solution applied during 15 s
(except 25 s for current-voltage experiments) followed by a 2 min buffer wash except for
nicotine application which received a 5 min buffer wash. Dose-response measurements
utilized a series of ~3-fold concentration steps, spanning several orders of magnitude, for a
total of eight to eighteen doses. Data were low-passed filtered at 5 Hz and digitized at 125
Hz.
Mecamylamine experiments involved three acetylcholine doses, followed by two co-
application doses of acetylcholine and mecamylamine, followed by two doses of
acetylcholine only. Before each co-application, there was a 30 s pre-incubation of
mecamylamine only.
2.3. Data Analysis
2.3.1. Dose-response Analysis—Averaged and normalized data were fit to one or two
Hill terms to generate EC50 and Hill coefficient (nH) values. All currents for the
mecamylamine experiment were normalized to the highest current response pre-
mecamylamine addition. The percentage recovery was calculated by comparing pre-and
post-mecamylamine applications.
2.3.2. Current-voltage analysis—I–V relations were generated from 400 ms test pulses,
applied at intervals of 500 ms, ranging from −110 mV to +70 mV in 20 mV increments. To
minimize distortions from desensitization or ion accumulation, the increments proceeded in
both depolarizing and hyperpolarizing directions during each drug application, and averaged
data were analyzed. To isolate agonist-induced currents, we subtracted records taken in
buffer only. The current was averaged during 200 to 400 ms after the jump, and then
normalized to the value at −110 mV.
2.3.3. Error Analysis—Error bars on dose-response curves represent standard error of the
mean (SEM) values. Maximal current values (wild type vs. V9'S α5 subunit) and voltage
jump comparisons (at +70 mV) were subjected to Student t Test analysis and gave t
probabilities < 0.001.
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3. Results
3.1. Expression of an α5-containing receptor
Accurate interpretation of structure-function relationships from electrophysiological
responses requires expression of a homogeneous receptor population. As such, a method to
prepare and confirm a homogenous population of α5* receptors must first be established
before we can begin to interpret results from mutational analysis of the putative α5–α4
interface. α5 presents a unique challenge because of its role as an accessory subunit. When
α5 is co-expressed with α4 and β2 subunits, we consider the possibility of three different
receptor populations on the cell surface: (α4β2)2(β2), (α4β2)2(α4) and (α4β2)2(α5). The
assumption that α4β2α5 receptors have an (α4β2)2(α5) stoichiometry is partly based on
analogy to the muscle-type receptor, which contains two conventional binding interfaces (α/
γ(ε) and α/δ) and then a single auxiliary subunit, β. Previously, differences in EC50 values
and rectification behaviors allowed a distinction to be made between the two α4β2 receptor
stoichiometries (Xiu et al., 2009). Here, we apply similar strategies to evaluate α5*
receptors.
Varying mRNA injection ratios in oocytes can bias assembly to a specific receptor
stoichiometry (Moroni et al., 2006; Nelson et al., 2003; Xiu et al., 2009). Specifically, using
excess of α5 mRNA compared to α4 and β2 mRNA promotes preferential assembly with an
α5 subunit (Ramirez-Latorre et al., 1996). A ratio of 10:1:1 of α5:α4:β2 mRNA was used to
bias the system toward incorporation of the α5 subunit. As seen in (Fig. 2), injection of a 1:1
ratio of α4:β2 mRNA produces a biphasic dose-response relation, reflecting the presence of
A2B3 (high affinity) and A3B2 (low affinity) forms of the α4β2 receptor. However, a
monophasic dose-response relation is clearly seen upon the addition of the α5 mRNA
(Ramirez-Latorre et al., 1996). mRNA injections of 1:2 of α4:β2 (resulting in A2B3
receptors) and 10:1 of α4:β2 (resulting in A3B2 receptors) were performed in order to
compare EC50 values of the two α4β2 receptor stoichiometries with the new value obtained
from introducing the α5 mRNA (Fig. 2, Table 1). We find that the EC50 value resulting
from 10:1:1 α5:α4:β2 mRNA injection is nearly identical to that for the A2B3 receptor. This
could indicate that α5-containing receptors coincidentally have nearly the same EC50 as
A2B3 α4β2 receptors, or that the addition of the α5 mRNA is attenuating the expression of
the A3B2 receptor, resulting in a single population of A2B3 receptors at the surface. An
additional challenge to evaluating these putative α4β2α5 receptors was the low agonist-
induced current (tens to hundreds of nA) seen in these experiments.
To address the first issue, we tested the response to voltage-jump protocols that we have
previously used to distinguish A2B3 and A3B2 α4β2 receptors (Xiu et al., 2009). Figure 3
shows that there is a distinct loss of rectification for receptors prepared by a 10:1:1 α5:α4:β2
mRNA injection compared to A2B3 and A3B2 receptors. This result suggests that we have
α5* receptors on the surface of the oocyte.
To overcome the small currents that were hampering our efforts to fully characterize these
channels, we introduced an often-used reporter mutation at the 9' position of the pore lining
M2 helix (Filatov and White, 1995; Kearney et al., 1996; Labarca et al., 1995; Zhong et al.,
1998). Mutations in this region frequently result in increased expression levels. In addition,
9' mutations typically cause a gain of function in the receptor, evidenced by a reduction in
EC50 values and due to an altered Popen, without affecting the ligand-binding domain
(Gleitsman et al., 2009). Most subunits of nAChRs have a conserved Leu at the 9' position,
but the accessory subunits α5 and β3 contain a Val in that position. The V9'T (Groot-
Kormelink et al., 2001) or V9'S (Li et al., 2011) mutation has been employed to study
α3β4α5 nAChRs, but not α4β2α5 nAChRs. In the present work a V9'S mutation was
introduced into the α5 subunit, and the above experiments were repeated with the α5V9'S
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subunit. Interestingly, we observe nearly identical EC50 values for (α4β2)2(α5) and
(α4β2)2(α5V9'S) as shown in (Fig. 2). However, a substantial increase in agonist-induced
current was observed (Table 1), and more consistent responses among batches of oocytes
were noted. These observations further support the notion that the α5 subunit has been
incorporated, since the only change between the experiments was the mutation in the α5
subunit.
3.2. The α5V9'S mutation confers distinct physical properties allowing for definitive
establishment of the subunit's incorporation
The two stoichiometries of the α4β2 receptor are distinguishable by their distinct EC50
values. However, their rectification properties are similar (Fig. 2,3, Table 1,2). Previous
studies have shown that introduction of an L9'A mutation in the α4 subunit changes the
rectification behavior of α4β2 receptors (Xiu et al., 2009). Xiu et al. report that the A2B3
receptor rectifies much more markedly than the A3B2 when the a4 L9'A mutation is present
(Xiu et al., 2009). Similarly, we find that introduction of the V9'S mutation to the α5 subunit
produces a more marked loss of rectification compared to the wild type α5 subunit (Fig. 3).
In anticipation of future studies on receptor trafficking and localization, we prepared
receptors with the V9'S mutation and meGFP inserted in the M3–M4 loop of the α5 subunit.
This receptor also gives a wild type EC50 and a loss of rectification (Table 1,2).
In addition to the EC50 and rectification data, we also sought to more fully characterize the
(α4β2)2(α5V9'S) receptor. Mecamylamine has been extensively characterized as an open
channel blocker with a slow wash off time for the α4β2 receptor (Papke et al., 2001). A
distinctive property of this open channel blocker is its “trapping” behavior: it associates and
disassociates preferentially from the open pore of the receptor (Lester, 1992). Because of the
prolonged wash off time, subsequent applications of an agonist are generally needed to
dissociate the molecule from the pore.
The results in Figure 4 show a dramatic difference between the (α4β2)2(α5V9'S) receptor
and the α4β2 receptor. When the α5V9'S subunit is present, mecamylamine washes off the
receptor completely within 120 s. We also find that introducing an L9'A mutation into the
α4 subunit results in mecamylamine successfully washing out of both the A2B3 and A3B2
receptors (Table 3). This suggests that the observed results with the α5V9'S subunit are due
to the 9' mutation rather than an intrinsic property of the subunit. However, this still
generates an important observation for this system. For studies of the (α4β2)2(α5V9'S)
receptor, the observation of nearly complete response recovery within 120 s indicates that
we have prepared a receptor population on the plasma membrane that is highly enriched in
α5* receptors, if not completely homogeneous. If a more mixed population containing both
α5* and α4β2 receptors was being expressed, the response would have recovered less fully.
Results from the rectification and open channel blocker experiments strongly indicate that
we are able to express on the oocyte surface an α5* receptor population that is homogeneous
or very nearly so. With this, we can now begin to investigate the α5–α4 interface, knowing
that responses from introduced mutations are directly due to changes in the (α4β2)2(α5V9'S)
receptor.
3.3. Mutational analysis of the aromatic box at the α5–α4 interface showed no functional
impact
The aromatic box of nAChR agonist binding sites is highly conserved and has been
extensively characterized (Cashin et al., 2005; Dougherty, 2008; Mu et al., 2003; Puskar et
al., 2011; Tavares et al., 2012)}. The aromatic box mediates an essential cation-π interaction
between the positively charged portion of the ligand and one (or occasionally two) of the
five aromatic residues (A, B, C1, C2, and D) of the aromatic box. In fact, this aromatic box
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structure has been seen in a wide range of binding sites for cationic structures (Dougherty,
2013). The sequence alignment in Figure 1 highlights the residues of interest for studying
the α5 subunit. Residues TrpB, TyrC2, and TyrA have previously been shown to be
involved in cation-π interactions in other receptors, and these residues would be part of the
principal component of an aromatic box contributed by α5 if an α5–α4 binding site exists.
The TrpD residue of the α5 subunit was also investigated to probe the possibility of agonist
binding at the β2–α5 interface. In addition, this mutation can subsequently probe the
possibility that α5 subunits were replacing β2 subunits that would normally participate in the
α4–β2 binding site. Interestingly, the C1 residue of the aromatic box that is typically a Tyr
in α subunits is an Asp in the α5 subunit.
An alanine scan of the aromatic residues of α5 was performed. As shown in Table 4,
negligible changes in EC50 were seen in all cases for both ACh and nicotine as agonists.
Since the C1 site is not aromatic in the α5 subunit, an Asp-to-Tyr mutation was introduced.
Again, no change in EC50 was seen. Current-voltage relations confirmed the inclusion of the
α5 subunit for all the mutations (data not shown).
4. Discussion
Accessory subunits play important roles in nAChR function, because they confer unique
properties to their parent receptors. Not surprisingly, expression of these subunits is highly
regulated and restricted to specific brain regions (Gotti et al., 2006; Miwa et al., 2011).
Some examples of this region specificity are found in the cerebral cortex, where α5*
receptors are expressed only in layer VI, and in the striatum, where α5 may be expressed
only in the dopaminergic neurons of the caudatoputamen, but not in the nucleus accumbens
region (Exley et al., 2012; Salas et al., 2003; Wada et al., 1990). α5 is of particular interest
because well-replicated human genome-wide association studies have identified a single
nucleotide polymorphism that affects the risk for nicotine dependence, lung cancer, and
alcohol dependence (Bierut, 2010; Hartz et al., 2012; Saccone et al., 2009). This mutation,
encoding Asn at position 398 in the coding region of the CHRNA5 gene, also affects
nicotine self-administration in mice (Fowler et al., 2011; Frahm et al., 2011). Thus, it would
be beneficial to be able to probe functional differences of α5* receptors using
pharmacological agents in vivo.
Here we aimed to elucidate possible ligand binding motifs involving the α5 subunit in the
(α4β2)2(α5) receptor. The α designation for a5 arose from the existence of adjacent Cys
residues in the C loop (Fig. 1B), although other aspects of the C loop such as replacement of
conserved TyrC1 and residue deletions are more β-like. Also, α5 is unable to form
functional receptors unless other α subunits are also expressed. As such, α5 is generally
considered to be an accessory subunit. However, the discovery of an α4–α4 binding
interface in A3B2 α4β2 receptors suggests the possibility of an unusual binding site at the
α5–α4 binding interface (Mazzaferro et al., 2011).
To address this question, we first optimized our expression system to ensure a
homogeneous, or at least very highly enriched, population of receptors. Early studies on
wild type receptors in oocytes suggested that biasing mRNA injection ratios strongly toward
α5 would produce a homogeneous population of α5-containing receptors. However,
expression levels were low, making thorough characterization challenging. Introducing a
V9'S mutation into the α5 subunit resulted in increased agonist responses, allowing greater
consistency and reproducibility between experiments.
We have two lines of evidence to support the argument that α5 is incorporated into the
receptor and that the population of receptors on the oocyte plasma membrane is
Marotta et al. Page 6
Neuropharmacology. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
homogeneous or very nearly so. First, we see altered rectification behavior for channels with
α5 vs. pure α4β2 receptors (Fig. 3). The effect is evident in fully wild type receptors, but is
more apparent for the α5 V9'S receptors. This is the second system for which we have
observed that a 9' mutation can markedly affect channel rectification properties. A single 9'
mutation in the accessory subunit location – α5V9'S in this case – is sufficient to alter the
rectification properties of the receptor. In the α4β2 receptor, the A3B2 receptor with the
L9'A mutation in the α4 subunit shows a marked loss of rectification, but replacing the third
α4 L9'A subunit with a β2 subunit (A2B3) restores rectification (Table 2) (Xiu et al., 2009).
The second argument for incorporation of α5 into our expressed receptors is based on
altered behavior by the channel blocker mecamylamine. For α4β2 receptors, mecamylamine
blockade washes out very slowly, and most efficiently when agonist is also added (Fig. 4B).
When the α5 V9'S subunit is included, mecamylamine blockade washes out readily. Note
that the washout is essentially complete, arguing that all, or very nearly all, receptors contain
the α5 subunit. Any population of α4β2 receptors would have led to residual mecamylamine
block. The alteration of mecamylamine block is only seen when the V9'S mutation is present
in α5. An α4 L9'A mutation also impacts mecamylamine block, indicating that it is the pore
mutation that is affecting block, not the intrinsic properties of the α5 subunit. Presumably,
mecamylamine binds within the pore near the 9' residue.
Having established that α5 is incorporated into the receptors, we can comment on its impact
on receptor function. It is interesting that the α4β2α5 receptor has essentially the same EC50
as the (α4β2)2(α4) receptor. This strongly suggests that the α5 subunit is not displacing an
α4 subunit that contributes to an agonist binding site, as this should produce an EC50
change, especially since any mutation of TyrC1 in nAChR agonist binding sites shifts EC50
strongly, and α5 is mutated at that site. The same argument could be made that α5 does not
replace a β2 subunit that contributes to the agonist binding site, although perhaps less
forcefully since the two have similar sequences in loop D. Note that if two (or more) α5
subunits were incorporated, then one of the canonical α4/β2 interfaces would disappear, and
again it is difficult to imagine that happening without EC50 being impacted. It is surprising
that the V9'S mutation in α5 does not shift EC50. Typically, introducing a polar substituent
at any 9' position of an nAChR leads to a drop in EC50. In other cases the wild type 9'
residue is Leu not Val, but it is not obvious why that would lead to a change in behavior
To probe for the existence of an agonist binding site at the α5–α4 interface, we mutated the
conserved residues in α5 that would contribute to the aromatic box of such a binding site
(TyrA, TrpB, TyrC1, and TyrC2). Converting an aromatic to an Ala or converting the Asp
that aligns with TyrC1 to Tyr did not have a marked affect on agonist responses. These are
fairly dramatic mutations that would produce very substantial shifts in EC50 in established
agonist binding sites. We also mutated TrpD of α5 to Ala, to probe whether α5 replaces a β2
subunit and contributes a complementary face, interacting with an α4 subunit. Again, no
meaningful impact on receptor function was seen.
The most straightforward interpretation of these results is that there is no ACh or nicotine
binding site at the α5–α4 interface, and so mutation of key residues has no functional
impact. We cannot rule out the possibility that ACh binds to the α5–α4 interface, but that
the binding does not meaningfully impact receptor function. Also, our assay precludes the
application of drugs at concentrations greater than 100 μM for α5* receptors, and so it is
possible that there is a very low affinity binding site (dissociation constant on the order of
mM). However, the biological implications of such a site seem negligible. Also, it is
possible that other drugs could bind at the α5–α4 interface, and that binding at the α5–α4
interface could have a functional consequence in receptors in which the conventional, α4–β2
interfaces have in some way been compromised.
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Although it does not contribute an ACh binding site in the nAChRs studied here, the α5
subunit can play other important roles. The α5 subunit also co-assembles with α3 and β4
subunits to form functional nAChRs, especially in peripheral ganglia and in the medial
habenula-interpeduncular nucleus pathway (Fowler et al., 2011), and it has been shown to
modulate expression levels of these receptors (George et al., 2012). Also, the α5 subunit
could impart pore-related differences such as Ca2+ permeability (Kuryatov et al., 2008), and
intracellular loop-related differences such as endoplasmic reticulum exit and synaptic
targeting (Gotti et al., 2005).
In conclusion, we have developed a protocol for preparing highly enriched populations of
(α4β2)2(α5) nAChRs, and we have shown that mutations that would be expected to disrupt
an α5–α4 interfacial binding site do not affect receptor function. In addition, we have shown
that α5 subunits only occupy the auxiliary position when co-assembled with α4 and β2
subunits. Further studies will be required to develop a strategy for selectively probing α5*
receptors with pharmacological agents.
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Highlights
• α4β2α5 receptors modulate rectification properties compared to α4β2 receptors
• α5V9'S allows generation and observation of a homogenous receptor population
• Mutational analysis shows no functional ligand binding site at the α5–α4
interface
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Fig. 1.
A. View of nAChRs from the extracellular solution. The α4β2 receptor has two α4 subunits,
two β2 subunits, and two conventional antagonist/agonist binding sites, at α4–β2 interfaces.
The fifth subunit is the “accessory” subunit, and in this study three possibilities are the α4,
α5 or β2 subunits. The accessory subunit may also contribute to a binding interface, shown
by “?” B. Sequence alignment of the mouse nAChR subunits highlighting the aromatic box
residue locations on loops D, A, B, and C (in sequence). The residues shown are identical to
their human sequence except the final residue (Cys) in the mouse α5 subunit is a tyrosine
(Tyr, Y) in the human subunit. Note that TrpD is on the “complementary” face of a subunit,
and so it is not expected to contribute to an α5–α4 interface.
Marotta et al. Page 13
Neuropharmacology. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
A. Dose response relations for the mouse α4β2 receptor with a 1:1 injection ratio, and for
the mouse (α4β2)2(α5) receptor with a 10:1:1 α5:α4:β2 mRNA injection ratio. B.
Comparison of dose-response relations for the two stoichiometries of the mouse α4β2
receptors (A2B3 and A3B2) and the mouse (α4β2)2(α5) receptor with and without the α5-
V9'S mutation.
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Fig. 3.
Summary of rectification analysis. A. Sample traces of the voltage jump experiment. The
superimposed command voltage sweeps (left) and the ACh-induced currents (right) for the
(α4β2)2(α5V9'S) receptor are shown. B. Comparison of current-voltage relations for the two
stoichiometries of the mouse α4β2 receptors (A2B3 and A3B2) and the mouse (α4β2)2(α5)
receptor with and without the 9' mutation.
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Fig. 4.
A. Response recovery following co-application of acetylcholine and mecamylamine
following the protocol in part B. B. A sample current trace of a single oocyte recording for
each of the subunit combinations indicated. The α4β2 nAChR is in red and the
(α4β2)2(α5V9'S) nAChR is in black. A 120 s wash period occurred between each dose.
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Table 1
EC50 values, Hill coefficients, and current ranges for receptors studied here.
Receptor (Ratio) EC50 (μM) Hill n Current Range (μA)
α4 wt β2 wt (1:1) 0.9 ± 0.2 (low) 0.9 ± 0.1 (low) 25 −0.14 to −7.0
110 ± 15 (high) 2.1 ± 0.5 (high) - -
α4 wt β2 wt (1:2) 0.80 ± 0.05 1.15 ± 0.7 13 −0.15 to −0.97
α4 wt β2 wt (10:1) 141 ± 27 2.0 ± 0.7 17 −1.5 to −16
α4L9'A β2 wt (1:10) 0.39 ± 0.02 1.25 ± 0.7 13 −0.31 to −7.2
α4L9'A β2 wt (10:1) 0.046 ± 0.001 1.27 ± 0.04 13 −4.1 to −22
α5 wt α4 wt β2 wt (10:1:1) 0.55 ± 0.05 0.95 ± 0.1 12 −0.027 to −0.20
α5V9'S α4 wt β2 wt (10:1:1) 0.57 ± 0.01 1.14 ± 0.01 26 −0.38 to −5.7
α5V9'S GFP α4 wt β2 wt (10:1:1) 0.76 ± 0.02 1.07 ± 0.03 17 −0.34 to −7.2
Agonist = Acetylcholine
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Table 2
Voltage jump results for receptors studied here.
Receptor (Ratio) ACh Induced Current at +70
mV (Normalized)
Current Range (μA) at
−110mV
Current Range (μA) at
+70mV n
α4 wt β2 wt (1:1*) 0.01 ± 0.01 −0.35 to −1.8 −0.02 to 0.11 34
α4 wt β2 wt (1:2) 0.01 ± 0.01 −0.10 to −1.4 −0.03 to 0.09 34
α4 wt β2 wt (10:1) 0.067 ± 0.008 −1.7 to −24 0.08 to 2.0 60
α4L9'A β2 wt (1:10) 0.054 ± 0.005 −0.23 to −5.0 −0.006 to 0.25 28
α4L9'A β2 wt (10:1) 0.34 ± 0.01 −1.0 to −18 0.39 to 6.4 31
α5 wt α4 wt β2 wt (10:1:1) 0.10 ± 0.03 −0.073 to −0.14 −0.013 to 0.027 6
α5V9'S α4 wt α2 wt (10:1:1) 0.34 ± 0.02 −0.56 to −2.5 0.15 to 1.2 34
α5V9'S GFP α4 wt β2 wt (10:1:1) 0.33 ± 0.02 −0.71 to −1.9 0.27 to 0.5 12
ACh doses were the corresponding receptor's EC50 value for the voltage jump experiments
*
The smaller of the two EC50 value was used for this measurement
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Table 3
Results of mecamylamine experiments.
Receptor (Ratio) Signal Recovery Current Range (μA) n
α5V9'S α4 wt β2 wt (10:1:1) 80 ± 2 % −0.46 to −1.0 14
α4 wt β2 wt (1:2) 12 ± 1 % −0.16 to −1.5 13
α4 wt β2 wt (10:1) 17 ± 2 % −1.3 to −22 16
α4L9'A β2 wt (1:10) 56 ± 2 % −0.08 to −0.84 15
α4L9'A β2 wt (10:1) 93 ± 5 % −1.3 to −20 14
ACh doses were 10 times the corresponding receptor's EC50 value for the mecamylamine experiments Mecamylamine was kept at constant 100
μM value to ensure full channel block
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